Siegel, R. L., Miller, Ok. D. & Jemal, A. Most cancers statistics, 2020. CA Most cancers J. Clin. 70, 7–30. https://doi.org/10.3322/caac.21590 (2020).
Siegel, R. L. et al. Colorectal most cancers statistics, 2017. CA Most cancers J. Clin. 67, 177–193. https://doi.org/10.3322/caac.21395 (2017).
Bray, F. et al. World most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 international locations. CA Most cancers J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
Corvino, A., Corvino, F., Radice, L. & Catalano, O. Synchronous mucinous colonic adenocarcinoma and a number of small intestinal adenocarcinomas: Report of a case and evaluate of literature. Clin. Imaging 39, 538–542. https://doi.org/10.1016/j.clinimag.2014.12.019 (2015).
Ullmann, P., Nurmik, M., Begaj, R., Haan, S. & Letellier, E. Hypoxia- and MicroRNA-induced metabolic reprogramming of tumor-initiating cells. Cells 8, 528. https://doi.org/10.3390/cells8060528 (2019).
O’Connell, J. B., Maggard, M. A. & Ko, C. Y. Colon most cancers survival charges with the brand new American Joint Committee on Most cancers sixth version staging. J. Natl. Most cancers Inst. 96, 1420–1425. https://doi.org/10.1093/jnci/djh275 (2004).
Dunne, P. D. et al. Difficult the most cancers molecular stratification dogma: Intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic worth in colorectal most cancers. Clin. Most cancers Res. 22, 4095–4104. https://doi.org/10.1158/1078-0432.ccr-16-0032 (2016).
Fletcher, R. H. Carcinoembryonic antigen. Ann. Intern. Med. 104, 66–73. https://doi.org/10.7326/0003-4819-104-1-66 (1986).
Chao, M. & Gibbs, P. Warning is required earlier than recommending routine carcinoembryonic antigen and imaging follow-up for sufferers with early-stage colon most cancers. J. Clin. Oncol. 27, e279-280. https://doi.org/10.1200/jco.2009.25.6156 (2009).
Hinoue, T. et al. Genome-scale evaluation of aberrant DNA methylation in colorectal most cancers. Genome Res. 22, 271–282. https://doi.org/10.1101/gr.117523.110 (2012).
Wooden, L. D. et al. The genomic landscapes of human breast and colorectal cancers. Science 318, 1108–1113. https://doi.org/10.1126/science.1145720 (2007).
Jones, P. A. & Baylin, S. B. The epigenomics of most cancers. Cell 128, 683–692. https://doi.org/10.1016/j.cell.2007.01.029 (2007).
Kulis, M. & Esteller, M. DNA methylation and most cancers. Adv. Genet. 70, 27–56. https://doi.org/10.1016/b978-0-12-380866-0.60002-2 (2010).
Klutstein, M., Nejman, D., Greenfield, R. & Cedar, H. DNA methylation in most cancers and growing old. Most cancers Res. 76, 3446–3450. https://doi.org/10.1158/0008-5472.can-15-3278 (2016).
Baylin, S. B. & Jones, P. A. A decade of exploring the most cancers epigenome—Organic and translational implications. Nat. Rev. Most cancers 11, 726–734. https://doi.org/10.1038/nrc3130 (2011).
Baylin, S. B. & Jones, P. A. Epigenetic determinants of most cancers. Chilly Spring Harbor Perspect. Biol. https://doi.org/10.1101/cshperspect.a019505 (2016).
Irizarry, R. A. et al. The human colon most cancers methylome exhibits related hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178–186. https://doi.org/10.1038/ng.298 (2009).
Tse, J. W. T., Jenkins, L. J., Chionh, F. & Mariadason, J. M. Aberrant DNA methylation in colorectal most cancers: What ought to we goal?. Tendencies Most cancers 3, 698–712. https://doi.org/10.1016/j.trecan.2017.08.003 (2017).
Huang, W. Y. et al. MethHC: A database of DNA methylation and gene expression in human most cancers. Nucleic Acids Res. 43, D856-861. https://doi.org/10.1093/nar/gku1151 (2015).
Farooqi, A. A., de la Roche, M., Djamgoz, M. B. A. & Siddik, Z. H. Overview of the oncogenic signaling pathways in colorectal most cancers: Mechanistic insights. Semin. Most cancers Biol. 58, 65–79. https://doi.org/10.1016/j.semcancer.2019.01.001 (2019).
Rawluszko, A. A., Bujnicka, Ok. E., Horbacka, Ok., Krokowicz, P. & Jagodziński, P. P. Expression and DNA methylation ranges of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal most cancers. BMC Most cancers 13, 526. https://doi.org/10.1186/1471-2407-13-526 (2013).
Alizadeh Naini, M. et al. O6-methyguanine-DNA methyl transferase (MGMT) promoter methylation in serum DNA of Iranian sufferers with colorectal most cancers. Asian Pac. J. Most cancers Prev. APJCP 19, 1223–1227. https://doi.org/10.22034/apjcp.2018.19.5.1223 (2018).
Semaan, A. et al. SEPT9 and SHOX2 DNA methylation standing and its utility within the prognosis of colonic adenomas and colorectal adenocarcinomas. Clin. Epigenet. 8, 100. https://doi.org/10.1186/s13148-016-0267-5 (2016).
Li, M. et al. A DNA methylation signature for the prediction of tumour recurrence in stage II colorectal most cancers. Br. J. Most cancers 128, 1681–1689. https://doi.org/10.1038/s41416-023-02155-8 (2023).
Cai, G. et al. A multilocus blood-based assay concentrating on circulating tumor dna methylation allows early detection and early relapse prediction of colorectal most cancers. Gastroenterology 161, 2053-2056 e2052. https://doi.org/10.1053/j.gastro.2021.08.054 (2021).
Mo, S. et al. Early detection of molecular residual illness and threat stratification for stage I to III colorectal most cancers by way of circulating tumor DNA methylation. JAMA Oncol. 9, 770–778. https://doi.org/10.1001/jamaoncol.2023.0425 (2023).
Guo, S., Diep, D., Plongthongkum, N., Fung, H. L. & Zhang, Ok. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat. Genet. 49, 635–642. https://doi.org/10.1038/ng.3805 (2017).
Krueger, F. & Andrews, S. R. Bismark: A versatile aligner and methylation caller for Bisulfite-Seq functions. Bioinformatics (Oxford, England) 27, 1571–1572. https://doi.org/10.1093/bioinformatics/btr167 (2011).
Langmead, B. Aligning brief sequencing reads with Bowtie. Curr. Protoc. Bioinform. https://doi.org/10.1002/0471250953.bi1107s32 (2010).
Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
da Huang, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative evaluation of huge gene lists utilizing DAVID bioinformatics assets. Nat. Protoc. 4, 44–57. https://doi.org/10.1038/nprot.2008.211 (2009).
Kanwal, R. & Gupta, S. Epigenetic modifications in most cancers. Clin. Genet. 81, 303–311. https://doi.org/10.1111/j.1399-0004.2011.01809.x (2012).
Pedersen, S. Ok. et al. Detection of methylated BCAT1 and IKZF1 after curative-intent therapy as a prognostic indicator for colorectal most cancers recurrence. Most cancers Med. 12, 1319–1329. https://doi.org/10.1002/cam4.5008 (2023).
Wang, W. et al. Recurrence threat evaluation for stage III colorectal most cancers based mostly on 5 methylation biomarkers in plasma cell-free DNA. J. Pathol. 259, 376–387. https://doi.org/10.1002/path.6047 (2023).
Fu, B. et al. Evaluation of DNA methylation-driven genes for predicting the prognosis of sufferers with colorectal most cancers. Growing old 12, 22814–22839. https://doi.org/10.18632/growing old.103949 (2020).
Yang, C., Zhang, Y., Xu, X. & Li, W. Molecular subtypes based mostly on DNA methylation predict prognosis in colon adenocarcinoma sufferers. Growing old 11, 11880–11892. https://doi.org/10.18632/growing old.102492 (2019).
Dai, Q. X. et al. A novel epigenetic signature to foretell recurrence-free survival in sufferers with colon most cancers. Clin. Chim. Acta Int. J. Clin. Chem. 508, 54–60. https://doi.org/10.1016/j.cca.2020.05.016 (2020).
Amini, M. et al. GHSR DNA hypermethylation is a brand new epigenetic biomarker for gastric adenocarcinoma and past. J. Cell. Physiol. 234, 15320–15329. https://doi.org/10.1002/jcp.28179 (2019).
Jandaghi, P., Hoheisel, J. D. & Riazalhosseini, Y. GHSR hypermethylation: A promising pan-cancer marker. Cell Cycle (Georgetown, Tex) 14, 689–690. https://doi.org/10.1080/15384101.2015.1006051 (2015).
Cook dinner, A. L. & Haynes, J. M. Protein kinase G II-mediated proliferative results in human cultured prostatic stromal cells. Cell. Sign. 16, 253–261. https://doi.org/10.1016/s0898-6568(03)00134-7 (2004).
Solar, X. et al. Genome-wide methylation and expression profiling determine methylation-associated genes in colorectal most cancers. Epigenomics 12, 19–36. https://doi.org/10.2217/epi-2019-0133 (2020).
Annaházi, A. et al. A pilot research on faecal MMP-9: A brand new noninvasive diagnostic marker of colorectal most cancers. Br. J. Most cancers 114, 787–792. https://doi.org/10.1038/bjc.2016.31 (2016).
Qiu, Z. et al. Downregulation of DUSP9 promotes tumor development and contributes to poor prognosis in human colorectal most cancers. Entrance. Oncol. 10, 547011. https://doi.org/10.3389/fonc.2020.547011 (2020).
Diamantopoulou, Z. et al. TIAM1 antagonizes TAZ/YAP each within the destruction advanced within the cytoplasm and within the nucleus to inhibit invasion of intestinal epithelial cells. Most cancers Cell 31, 621-634 e626. https://doi.org/10.1016/j.ccell.2017.03.007 (2017).
